Aligos Therapeutics Inc 2025年季度报告

(Mark One) ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF1934 OR For the transition period fromtoCommission File Number:001-39617 Aligos Therapeutics, Inc.(Exact Name of Registrant as Specified in its Charter) 82-4724808(I.R.S. EmployerIdentification No.) One Corporate Drive,2nd FloorSouth San Francisco,California(Address of principal executive offices) Registrant’s telephone number, including area code: (800)466-6059 Securities registered pursuant to Section 12(b) of the Act: Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of theSecurities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to filesuch reports), and (2) has been subject to such filing requirements for the past 90 days.Yes☒No☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to besubmitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorterperiod that the registrant was required to submit such files).Yes☒No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, asmaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,”“smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. Large acceleratedfiler☐Non-accelerated filer☒ Accelerated filer☐Smaller reporting company☒Emerging growthcompany☒ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition periodfor complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).Yes☐No☒ As of May 1, 2025, the registrant had6,114,801shares of common stock, $0.0001 par value per share, outstanding,comprised of5,314,801shares of voting common stock, $0.0001 par value per share and800,000shares of non-voting commonstock, $0.0001 par value per share. Special note regarding forward-looking statements This Quarterly Report on Form 10-Q contains forward-looking statements concerning our business, operations and financialperformance and condition, as well as our plans, objectives and expectations for our business, operations and financial performanceand condition. Any statements contained herein that are not statements of historical facts may be deemed to be forward-lookingstatements. These statements involve known and unknown risks, uncertainties and other important factors that are in some casesbeyond our control and may cause our actual results, performance or achievements to be materially different from any futureresults, performance or achievements expressed or implied by the forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “aim,” “anticipate,” “assume,” “believe,”“contemplate,” “continue,” “could,” “due,” “estimate,” “expect,” “goal,” “intend,” “may,” “objective,” “plan,” “predict,”“potential,” “positioned,” “seek,” “should,” “target,” “will,” “would,” and other similar expressions that are predictions of orindicate future events and future trends, or the negative of these terms or other comparable terminology. These forward-lookingstatements include, but are not limited to, statements about: •the scope, progress, results and costs of developing our drug candidates or any other future drug candidates, andconducting nonclinical studies and clinical trials;•the scope, progress, results and costs related to the research and development of our pipeline;•the timing of, and costs involved in, obtaining and maintaining regulatory approval for any of our current or future drugcandidates, and any related restrictions or limitations;•our expectations regarding the potential market size and size of the potential patient populations for our drug candidatesand any future drug candidates, if approved for commercial use;•our ability to maintain existing, and establish new, collaborations, licensing or other arrangements and the financialterms of any such agreements;•our commercialization, marketing and manufacturing capabilities and expectations;•the rate and degree of market acceptance of our drug candidates, as well as the pricing and reimbursement of our drugcandidates, if approved;•the implementation of our business model and strategic plans for our business, drug candidates and technology,including additional indications for which we may pursue;•the scope of protection we are able to establish and maintain for intellectual property rights covering our drugcandidates, including the projected term of patent protection;•any lawsuits related to our dru